Patents by Inventor Lorena Taboada Martinez

Lorena Taboada Martinez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydrotriazolopyridine compounds as selective MGLU5 receptor potentiators useful for the treatment of schizophrenia
    Patent number: 8592590
    Abstract: The present invention provides certain tetrahydrotriazolopyridine derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same. Formula (I) wherein R1 is hydrogen, fluoro, chloro, or methyl; and R2 is C4-CS branched alkyl.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: November 26, 2013
    Assignee: Eli Lilly and Company
    Inventors: Lourdes Prieto, Lorena Taboada Martinez
  • MGLU2 agonists
    Patent number: 8318184
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: November 27, 2012
    Assignee: Eli Lilly and Company
    Inventors: James Allen Monn, Lourdes Prieto, Lorena Taboada Martinez, Carlos Montero Salgado, Bruce William Shaw
  • TETRAHYDROTRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE MGLU5 RECEPTOR POTENTIATORS USEFUL FOR THE TREATMENT OF SCHIZOPHRENIA
    Publication number: 20120252838
    Abstract: The present invention provides certain tetrahydrotriazolopyridine derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same. Formula (I) wherein R1 is hydrogen, fluoro, chloro, or methyl; and R2 is C4-CS branched alkyl.
    Type: Application
    Filed: December 21, 2010
    Publication date: October 4, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Lourdes Prieto, Lorena Taboada Martinez
  • MGLU2 AGONISTS
    Publication number: 20110152334
    Abstract: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: James Allen MONN, Lourdes PRIETO, Lorena TABOADA MARTINEZ, Carlos Montero SALGADO, Bruce William SHAW